Boston Scientific has settled three patent disputes with Johnson & Johnson (J&J) for $1.73 billion.
Boston Scientific will pay Cordis $716.3 million to resolve more than a dozen lawsuits over the Palmaz infringement suit relating to Boston Scientific’s NIR stent and several other cardiology cases relating to patents in the Ding, Kastenhofer, Palmaz and Fontirroche patent families, and exchanging paid-up licenses for certain intellectual properties.
Boston Scientific has received FDA approval to market its Taxus Liberte Long paclitaxel-eluting coronary stent system, a drug-eluting stent (DES) designed for long lesions.
Boston Scientific has submitted to the FDA the final modules of its pre-market approval (PMA) applications for both its Taxus Liberte Atom paclitaxel-eluting coronary stent system and its Taxus Liberte Long paclitaxel-eluting coronary stent system.
|
The everolimus-eluting stent is better than the second-generation paclitaxel-eluting stent (Taxus Liberte, Boston Scientific) in unselected patients undergoing PCI in terms of safety and efficacy, concluded the COMPARE trial that was published Jan. 7 in Lancet. Based on these findings, the authors suggest that paclitaxel-eluting stents should no longer be used in everyday clinical practice.
New Jersey radiologist Bruce N. Saffran, MD, who was awarded about $500 million in a 2008 patent infringement case against Boston Scientific, filed suit Monday in the U.S. District Court for the Eastern District of Texas over Abbott's Xience V everolimus-eluting coronary stent.
Boston Scientific has received approval from the FDA to market its Taxus Liberte Atom paclitaxel-eluting coronary stent system, a drug-eluting stent (DES) designed for treating small coronary vessels, as small as 2.25 mm in diameter.
Boston Scientific has received approval from the FDA to market its second-generation Taxus Liberte paclitaxel-eluting coronary stent system.
|
RSS 
Middle age introduces itself in many ways; one is atrial fibrillation (AF). My onset of AF seems to have coincided with a mountain bike accident in the woods of North Carolina that resulted in some cracked ribs.
The use of health IT to reduce rehospitalizations will be welcome but also disruptive, said Stephen Jencks, an independent consultant in healthcare safety during a Feb. 24 webinar on the potential use of health IT to mitigate rehospitalizations, sponsored by the Agency for Healthcare Research and Quality (AHRQ).
A new hospital breaking ground usually isn’t breaking news. But the vision of patient care at one new facility, tentatively named Palomar Medical Center West (PMC West), is currently illegal under California state law.
There are cases presented to all physicians when we have to balance benefits of a particular treatment with concerns around safety for certain patients. In interventional cardiology, we see this dilemma with drug-eluting stents (DES). While this technology provides effective therapy for many patients with ischemia-inducing coronary lesions, there are certain patient groups that encounter problems for different reasons.
U.S. News & World Report and HealthGrades surveys that rank “Best Hospitals” according to their high-quality cardiovascular care do not create the most comprehensive list and may create confusion by excluding hospitals that provide the same quality of care, according to a study published in the January issue of the Journal of the American College of Surgeons.